Our 2-year longitudinal study showed no effect of glatiramer therapy on cognitive function in relapsing-remitting MS. Although it is possible that glatiramer therapy has no effect on cognitive function, the lack of measurable decline in cognitive function in both patient groups for 2 years limits the opportunity for glatiramer to demonstrate a therapeutic effect by minimizing such decline. Emerging treatments for MS should continue to be examined for their effect on cognitive impairment because it can be a critical determinant of disability. A greater understanding of the natural history of cognitive decline in MS is essential for a rational design of these drug trials.

No abstract

We evaluated six patients with vertebrobasilar dolichoectasia (VBD) comparing clinical presentation with magnetic resonance (MR) and computed tomography (CT) imaging. MR diagnosed the condition as well as CT in all cases, but proved superior to CT in delineating the anatomical relationship of the vessels to the neural structures. MR proved especially useful in cases of VBD-associated hydrocephalus and posterior fossa masses. A coexisting tumor was diagnosed by MR in one case.

Six patients presenting with new neurological deficits underwent magnetic resonance imaging (MRI) that displayed mass lesions leading to diagnoses of tumor or abscess. Biopsy revealed demyelinating lesions.